GlaxoSmithKline finds Nucala can be used to treat severe asthma

GlaxoSmithKline has presented new new safety and efficacy data for Nucala to treat severe asthma with an eosinophilic phenotype.

The data shows that exacerbation risk reduction, asthma control improvement and oral corticosteroid dose reduction seen in earlier trials was also demonstrated in the latest study.

Frank Albers, Global Medical Affairs Lead for Nucala, GSK said: "Severe asthma with an eosinophilic phenotype is a chronic condition that affects a small, but significant, number of patients who need to take multiple medications to control their day-to-day symptoms and reduce the risk of frequent and serious asthma attacks."

The results showed a long-term safety profile and durable response to Nucala, which was specifically developed for these difficult-to-treat patients. Researchers are confident that the study has strengthened understandings of this novel therapeutic approach.